Regeneron Pharmaceuticals (REGN) Stock Forecast: What Could Drive It in 2026
Short answer
What is actually driving Regeneron Pharmaceuticals (REGN) right now is Dupixent keeps compounding: Dupixent remains the central growth driver, with global net sales rising about 31% to roughly $4.9 billion in Q1 2026 and label expansions into conditions like COPD and chronic spontaneous urticaria widening the addressable population. Total revenue (TTM, approx) is ~$14 billion. If that keeps playing out, the setup is favourable; the risk to it is the clearest risk is Eylea biosimilar erosion. No one can predict where REGN trades, and Walnut does not publish targets, so treat this as a scenario, not a price target or prediction.
What could drive Regeneron Pharmaceuticals (REGN) higher?
Dupixent keeps compounding
Dupixent remains the central growth driver, with global net sales rising about 31% to roughly $4.9 billion in Q1 2026 and label expansions into conditions like COPD and chronic spontaneous urticaria widening the addressable population. Because Regeneron splits economics with Sanofi, growth flows through as rising collaboration revenue. As long as new indications and geographies keep landing, this franchise can offset pressure elsewhere in the portfolio.
A deep, diversified pipeline
Regeneron carries nearly 50 clinical candidates across roughly six therapeutic areas, including hematology-oncology, complement-mediated diseases, and anticoagulation. The company also logged its first gene therapy approval, signaling expansion beyond antibodies. This breadth means the investment case does not rest on any single readout, though individual trials still carry binary outcomes.
R&D productivity as a moat
The VelociSuite platform and Regeneron Genetics Center give the company an internal discovery engine that has repeatedly produced approved medicines without relying on large acquisitions. Planned R&D investment of roughly $6.6 billion in 2026 reflects management's bet that this engine keeps generating the next franchises. Investors who value durable innovation tend to anchor on this capability rather than any one drug.
Oncology optionality
Libtayo anchors a growing oncology effort, with fianlimab and other programs advancing in late-stage development. Oncology could become a third major pillar alongside immunology and eye disease over time. It is earlier in its revenue contribution, so it represents upside optionality more than a current cash driver.
What could weigh on REGN?
The clearest risk is Eylea biosimilar erosion. Amgen's Pavblu launched in late 2024 and pressured sales, and settlements clear paths for Sandoz, and Alvotech and Teva, to launch competing copies in the U.S. around the fourth quarter of 2026, with erosion expected to accelerate. Eylea HD and Dupixent growth are the offsets, but the timing gap matters. The business is also concentrated in a few franchises, so a single setback in Dupixent or a major pipeline failure would weigh heavily, and the collaboration structure with Sanofi means Regeneron does not control all of its largest product's economics.
How to think about a REGN forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the REGN guide and whether REGN is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the REGN outlook
The bottom line: what is driving Regeneron Pharmaceuticals (REGN) is Dupixent keeps compounding, with total revenue (ttm, approx) at ~$14 billion. If that keeps playing out the setup is favourable; the risk is the clearest risk is Eylea biosimilar erosion. No one can predict the price, so treat any REGN forecast as a scenario, not a target or prediction, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
Build a basket around REGN with Walnut
Use Regeneron Pharmaceuticals as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for Regeneron Pharmaceuticals (REGN)?
+
No one can reliably predict where REGN will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push Regeneron Pharmaceuticals higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive REGN higher?
+
The main growth drivers are Dupixent keeps compounding; A deep, diversified pipeline; R&D productivity as a moat. Whether they play out is the real question, not a guaranteed path.
What are the risks to REGN?
+
The clearest risk is Eylea biosimilar erosion. Amgen's Pavblu launched in late 2024 and pressured sales, and settlements clear paths for Sandoz, and Alvotech and Teva, to launch competing copies in the U.S. around the fourth quarter of 2026, with erosion expected to accelerate. Eylea HD and Dupixent growth are the offsets, but the timing gap matters. The business is also concentrated in a few franchises, so a single setback in Dupixent or a major pipeline failure would weigh heavily, and the collaboration structure with Sanofi means Regeneron does not control all of its largest product's economics.
Will REGN stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. Regeneron Pharmaceuticals's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is REGN a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the REGN "is it a buy?" page for a framework. Walnut is not an investment adviser.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.